Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Drops By 23.0%

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 3,456 shares, a decline of 23.0% from the March 31st total of 4,487 shares. Based on an average trading volume of 5,647 shares, the short-interest ratio is currently 0.6 days.

Jasper Therapeutics Price Performance

Shares of JSPRW traded down $0.00 during mid-day trading on Wednesday, hitting $0.02. 121 shares of the company traded hands, compared to its average volume of 21,527. The business has a 50-day moving average of $0.02 and a 200 day moving average of $0.06. Jasper Therapeutics has a one year low of $0.02 and a one year high of $0.18.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.